News | April 07, 2008

CAD Risk Less, Endothelial Function Improved in Cleaner Environment

April 8, 2008 - A study using Itamar Medical's Endo-PAT2000, an FDA-cleared device used to assess endothelial function, found that when indoor air particles are reduced in a controlled study environment, endothelial function, an indicator of cardiovascular health, significantly improves.

Itamar Medical's Endo-PAT2000 was used for evaluating the effect of high-efficiency particulate air (HEPA) filters on endothelial function in healthy elderly patients residing close to major roads. Vaclavik et al. found that air filtration significantly improved endothelial function in the study subjects (Vaclavik et al. Indoor Particles Affect Vascular Function in the Aged. American Journal of Respiratory and Critical Care Medicine 2008; Vol 177. pp. 419-425). Endothelial function is an important indicator of vascular health, so much so that endothelial dysfunction has been described as the "ultimate risk of risk factors" (Bonetti et al., Endothelial Dysfunction: A Marker of Atherosclerotic Risk, ATVB, 2003;23;168-175).

Both short-term and long-term exposure to ambient levels of particulate are associated with increased fatalities related to respiratory and cardiovascular disease. Researchers in the study believe endothelial dysfunction, which is a strong predictor of adverse cardiovascular conditions, may be the source of this increase in respiratory and cardiovascular diseases.

For more information: www.itamar-medical.com

Related Content

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Overlay Init